Assessment of islet function following islet and pancreas transplantation

Current Diabetes Reports

Volumn 6, Issue 4, 2006, Pages 316-322

  Dy, Emily C ^b   Harlan, David M ^b   Rother, Kristina I ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C PEPTIDE; CORTICOSTEROID; DACLIZUMAB; GLUCOSE; IMMUNOSUPPRESSIVE AGENT; INSULIN; INSULIN GLARGINE; INSULIN SENSITIZING AGENT; METFORMIN; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ANEMIA; DISEASE EXACERBATION; ENDOCRINE PANCREAS FUNCTION TEST; FOLLOW UP; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GRAFT RECIPIENT; GRAFT REJECTION; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOGLYCEMIA; IMAGING SYSTEM; INTRAVENOUS GLUCOSE TOLERANCE TEST; KIDNEY DISEASE; LIVER METABOLISM; NEPHROTOXICITY; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PATIENT MONITORING; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; PANCREAS TRANSPLANTATION; PEPTIDE HORMONES; TREATMENT OUTCOME;

EID: 33748305531     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-006-0067-y     Document Type: Review

References (53)

1. Gruessner AC, Sutherland DE: Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin Transplant 2005, 19:433-455.
2. Sutherland DE, Gruessner RW, Dunn DL, et al.: Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg 2001, 233:463-501.
3. Robertson RP, Davis C, Larsen J, et al.: Pancreas transplantation for patients with type 1 diabetes. Diabetes Care 2003, 26(suppl 1):S120.
4. Landgraf R: Impact of pancreas transplantation on diabetic secondary complications and quality of life. Diabetologia 1996, 39:1415-1424.
5. Venstrom JM, McBride MA, Rother KI, et al.: Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA 2003, 290:2817-2823.
6. Joist H, Brennan DC, Coyne DW: Anemia in the kidney-transplant patient. Adv Chronic Kidney Dis 2006, 13:4-10.
7. Boratynska M, Banasik M, Watorek E, et al.: Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc 2006, 38:101-104.
8. Williams D, Haragsim L: Calcineurin nephrotoxicity. Adv Chronic Kidney Dis 2006, 13:47-55.
9. Najarian JS, Sutherland DE, Matas AJ, et al.: Human islet transplantation: a preliminary report. Transplant Proc 1977, 9:233-236.
10. Largiader F, Kolb E, Binswanger U: A long-term functioning human pancreatic islet allotransplant. Transplantation 1980, 29:76-77.
11. Scharp DW, Lacy PE, Santiago JV, et al.: Insulin independence after islet transplantation into type I diabetic patient. Diabetes 1990, 39:515-518.
12. Ricordi C, Lacy PE, Finke EH, et al.: Automated method for isolation of human pancreatic islets. Diabetes 1988, 37:413-420.
13. Shapiro AM, Lakey JR, Ryan EA, et al.: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000, 343:230-238.
14. Hirshberg B, Rother KI, Digon BJ III, et al.: Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care 2003, 26:3288-3295.
15. Rother KI, Harlan DM: Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J Clin Invest 2004, 114:877-883.
16. Luzi L, Hering BJ, Socci C, et al.: Metabolic effects of successful intraportal islet transplantation in insulin-dependent diabetes mellitus. J Clin Invest 1996, 97:2611-2618.
17. Diem P, Redmon JB, Abid M, et al.: Glucagon, catecholamine and pancreatic polypeptide secretion in type I diabetic recipients of pancreas allografts. J Clin Invest 1990, 86:2008-2013.
18. Ryan EA, Lakey JR, Paty BW, et al.: Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002, 51:2148-2157.
19. Ryan EA, Paty BW, Senior PA, et al.: Five-year follow-up after clinical islet transplantation. Diabetes 2005, 54:2060-2069.
20. Evgenov NV, Medarova Z, Dai G, et al.: In vivo imaging of islet transplantation. Nat Med 2006, 12:144-148.
21. Paty BW, Bonner-Weir S, Laughlin MR, et al.: Toward development of imaging modalities for islets after transplantation: insights from the National Institutes of Health Workshop on Beta Cell Imaging. Transplantation 2004, 77:1133-1137.
22. Christiansen E, Kjems LL, Volund A, et al.: Insulin secretion rates estimated by two mathematical methods in pancreas-kidney transplant recipients. Am J Physiol 1998, 274(4 Pt 1):E716-E725.
23. Sutherland DE, Gruessner A, Hering BJ: Beta-cell replacement therapy (pancreas and islet transplantation) for treatment of diabetes mellitus: an integrated approach. Endocrinol Metab Clin North Am 2004, 33:135-148, x.
24. Robertson RP, Sutherland DE, Kendall DM, et al.: Metabolic characterization of long-term successful pancreas transplants in type I diabetes. J Investig Med 1996, 44:549-555.
25. Bhargava R, Senior PA, Ackerman TE, et al.: Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes 2004, 53:1311-1317.
26. Eckhard M, Lommel D, Hackstein N, et al.: Disseminated periportal fatty degeneration after allogeneic intraportal islet transplantation in a patient with type 1 diabetes mellitus: a case report. Transplant Proc 2004, 36:1111-1116.
27. Maffi P, Angeli E, Bertuzzi F, et al.: Minimal focal steatosis of liver after islet transplantation in humans: a long-term study. Cell Transplant 2005, 14:727-733.
28. Markmann JF, Rosen M, Siegelman ES, et al.: Magnetic resonance-defined periportal steatosis following intraportal islet transplantation: a functional footprint of islet graft survival? Diabetes 2003, 52:1591-1594.
29. Toso C, Zaidi H, Morel P, et al.: Positron-emission tomography imaging of early events after transplantation of islets of Langerhans. Transplantation 2005, 79:353-355.
30. Ricordi C, Tzakis AG, Carroll PB, et al.: Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation 1992, 53:407-414.
31. Oberholzer J, Triponez F, Mage R, et al.: Human islet transplantation: lessons from13 autologous and 13 allogeneic transplantations. Transplantation 2000, 69:1115-1123.
32. Luzi L, Perseghin G, Brendel MD, et al.: Metabolic effects of restoring partial beta-cell function after islet allotransplantation in type 1 diabetic patients. Diabetes 2001, 50:277-282.
33. Rickels MR, Schutta MH, Markmann JF, et al.: Beta-cell function following human islet transplantation for type 1 diabetes. Diabetes 2005, 54:100-106.
34. Blackman JD, Polonsky KS, Jaspan JB, et al.: Insulin secretory profiles and C-peptide clearance kinetics at 6 months and 2 years after kidney-pancreas transplantation. Diabetes 1992, 41:1346-1354.
35. Robertson RP, Sutherland DE, Lanz KJ: Normoglycemia and preserved insulin secretory reserve in diabetic patients 10-18 years after pancreas transplantation. Diabetes 1999, 48:1737-1740.
36. Kaufman DB, Leventhal JR, Gallon LG, et al.: Technical and immunologic progress in simultaneous pancreas-kidney transplantation. Surgery 2002, 132:545-553.
37. Dieterle CD, Schmauss S, Veitenhansl M, et al.: Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimus. Transplantation 2004, 77:1561-1565.
38. Dupre J, Curtis JD, Unger RH, et al.: Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man. J Clin Invest 1969, 48:745-757.
39. Samols E, Marri G, Marks V. Promotion of insulin secretion by glucagon. Lancet 1965, 40:415-416.
40. Alejandro R, Lehmann R, Ricordi C, et al.: Long-term function (6 years) of islet allografts in type 1 diabetes. Diabetes 1997, 46:1983-1989.
41. Service FJ, Molnar GD, Rosevear JW, et al.: Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970, 19:644-655.
42. Matsumoto S, Yamada Y, Okitsu T, et al.: Simple evaluation of engraftment by secretory unit of islet transplant objects for living donor and cadaveric donor fresh or cultured islet transplantation. Transplant Proc 2005, 37:3435-3437.
43. Ryan EA, Paty BW, Senior PA, et al.: Beta-score: an assessment of beta-cell function after islet transplantation. Diabetes Care 2005, 28:343-347.
44. Paty BW, Ryan EA, Shapiro AM, et al.: Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin independence. Diabetes 2002, 51:3428-3434.
45. Gupta V, Wahoff DC, Rooney DP, et al.: The defective glucagon response from transplanted intrahepatic pancreatic islets during hypoglycemia is transplantation site-determined. Diabetes 1997, 46:28-33.
46. Hirshberg B, Mog S, Patterson N, et al.: Histopathological study of intrahepatic islets transplanted in the nonhuman primate model using Edmonton protocol immunosuppression. J Clin Endocrinol Metab 2002, 87:5424-5429.
47. Fowler M, Virostko J, Chen Z, et al.: Assessment of pancreatic islet mass after islet transplantation using in vivo bioluminescence imaging. Transplantation 2005, 79:768-776.
48. Dombrowski F, Mathieu C, Evert M: Hepatocellular neoplasms induced by low-number pancreatic islet transplants in autoimmune diabetic BB/Pfd rats. Cancer Res 2006, 66:1833-1843.
49. Ichii H, Inverardi L, Pileggi A, et al.: A novel method for the assessment of cellular composition and beta-cell viability in human islet preparations. Am J Transplant 2005, 5:1635-1645.
50. Latif ZA, Noel J, Alejandro R: A simple method of staining fresh and cultured islets. Transplantation 1988, 45:827-830.
51. Sabek OM, Marshall DR, Minoru O, et al.: OP-142 gene expression profile of nonfunctional human pancreatic islets: predictors of transplant failure? Transplant Proc 2005, 37:3441-3443.
52. Sweet IR, Khalil G, Wallen AR, et al.: Continuous measurement of oxygen consumption by pancreatic islets. Diabetes Technol Ther 2002, 4:661-672.
53. Teuscher AU, Kendall DM, Smets YF, et al.: Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes 1998, 47:324-330.